Stock TRDA ENTRADA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Entrada Therapeutics, Inc.

Equities

TRDA

US29384C1080

Market Closed - Nasdaq
Other stock markets
 21:00:00 21/05/2024 BST 		5-day change 1st Jan Change
15.7 USD +2.48% Intraday chart for Entrada Therapeutics, Inc. +10.64% +4.04%
05-20 Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing MT
05-16 Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Entrada Therapeutics Insider Sold Shares Worth $287,695, According to a Recent SEC Filing
MT
Entrada Therapeutics Insider Bought Shares Worth $364,673, According to a Recent SEC Filing
MT
Entrada Therapeutics to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference at NASDAQ
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Entrada Therapeutics Reports First Quarter 2024 Financial Results
GL
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Entrada Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
CI
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
GL
North American Morning Briefing : Stock Futures -2-
DJ
Entrada Therapeutics : Corporate Presentation
PU
Entrada Therapeutics to Present at Upcoming Investor Conferences
GL
Oppenheimer Starts Entrada Therapeutics With Outperform Rating, Price Target is $22
MT
Entrada Therapeutics Adds President Role to COO Nathan Dowden
MT
Entrada Therapeutics Adds President Role to COO Nathan Dowden
MT
Sector Update: Health Care Stocks Gain Pre-Bell Wednesday
MT
Entrada Therapeutics Promotes Nathan J. Dowden to President
GL
Entrada Therapeutics Promotes Nathan J. Dowden to President
CI
Pomerantz Law Firm Investigates Claims On Entrada Therapeutics, Inc. - TRDA
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TRDA Stock
  4. News Entrada Therapeutics, Inc.